70-Gene classifier for differentiation between paclitaxel- and docetaxel-sensitive breast cancers.

Area of Science:

• Oncology
• Molecular Biology
• Genomics

Background:

• Neoadjuvant chemotherapy is crucial for breast cancer treatment.
• Predictive biomarkers are needed to personalize neoadjuvant therapy with taxanes.
• Estrogen receptor (ER), progesterone receptor (PR), HER2, Ki67, and gene expression profiles are potential markers.

Purpose of the Study:

• To investigate the association of ER, PR, HER2, Ki67, and the 70-gene classifier (70-GC) with treatment response to paclitaxel (PAC) and docetaxel (DOC) in neoadjuvant breast cancer.
• To determine if 70-GC can differentiate between PAC-sensitive and DOC-sensitive tumors.

Main Methods:

• Retrospective analysis of breast cancer patients (n=79 for PAC, n=55 for DOC) receiving neoadjuvant taxane therapy.
• Assessed ER, PR, HER2, and Ki67 status.
• Utilized the 70-gene classifier (70-GC) for tumor classification.
• Evaluated tumor response rates to PAC and DOC based on biomarker status.

Main Results:

• Tumor sensitivity to PAC, but not DOC, was significantly associated with ER negativity (P=0.003), PR negativity (P=0.007), and Ki67 positivity (P=0.007).
• Tumors classified as responders by 70-GC showed a significantly higher reduction rate to PAC (P=0.005).
• Conversely, 70-GC responder tumors exhibited a significantly lower reduction rate to DOC (P=0.009) compared to non-responders.

Conclusions:

• ER negativity, PR negativity, and Ki67 positivity are significant predictors of PAC sensitivity in neoadjuvant breast cancer.
• The 70-gene classifier (70-GC) shows potential utility in distinguishing between tumors that are sensitive to PAC versus DOC.
• These findings support the use of biomarkers for tailoring neoadjuvant taxane therapy in breast cancer.